This company has been acquired
Blueprint Medicines Management
Management Kriterienprüfungen 2/4
Blueprint Medicines CEO ist Kate Haviland , ernannt in Apr 2022, hat eine Amtszeit von 3.25 Jahren. Die jährliche Gesamtvergütung beträgt $13.48M , bestehend aus 6.1% Gehalt und 93.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.11% der Aktien des Unternehmens, im Wert von $9.14M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5 Jahre bzw. 10.2 Jahre.
Wichtige Informationen
Kate Haviland
Geschäftsführender
US$13.5m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 6.09% |
| Amtszeit als Geschäftsführer | 3.3yrs |
| Eigentum des Geschäftsführers | 0.1% |
| Durchschnittliche Amtszeit des Managements | 5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 10.2yrs |
Jüngste Management Updates
Recent updates
Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade
Summary Sanofi's deal to acquire Blueprint was announced on June 2nd ,for an initial amount of $9.1bn, or $129 per share. Sanoi will acquire Blueprint's approved drug for mastocytosis Aykavit, which earned $150m last quarter, and could reach $2bn in revenues by 2030. There are contingent value rights that may pay up to $6 per share based on a pipeline drug, BLU-808, achieving certain milestones. Sanofi had the money and the desire to do the deal, and the price paid will likely satisfy Bluerprint shareholders - up >600% since IPO. This is, therefore, a good deal for Sanofi, and Blueprint, and could kick off a bull run on stock, as Aykavit will be immediately revenue accretive. Read the full article on Seeking Alpha
Expanding Patient Reach And Pipeline Development Will Unlock Potential
Strong AYVAKIT demand, expanded market reach, and improved therapy duration fuel revenue growth and enhance operating margin stability.Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock
Summary Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects Ayvakit to reach $2 billion in annual revenues by 2030, with significant growth potential as only 10% of the diagnosed SM market is penetrated. Blueprint is developing next-generation drugs like elenestinib and BLU-808, which could further enhance its SM franchise and diversify its revenue streams. Despite impressive growth and a strong cash position, I recommend a "hold" due to the stock's high valuation and the need for pipeline drugs to be further derisked. Read the full article on Seeking AlphaBlueprint Medicines: Growth For The Long Term Still Mostly Priced In
Summary Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging net product revenue at $435-$450 million, a ~117% increase from 2023. CEO Haviland highlights AYVAKIT's multibillion-dollar potential, driven by its unique value proposition and strong adoption among physicians, patients, and payers. Blueprint's revised revenue guidance is based on strong first-half 2024 performance and growing experience with factors driving its business, particularly in systemic mastocytosis treatment. Read the full article on Seeking AlphaBlueprint Medicines: Overdue For A Breather
Summary Today, we take a look at Blueprint Medicines Corporation, a company focused on developing precision therapies for cancers and blood disorders. Blueprint's Q1 results were spectacular, and the company has a solid balance sheet, but the stock is up more than 150% from its lows in late October. Can the shares rally further, or are they overdue for a breather? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaBlueprint Medicines: Rampant Growth Mostly Priced In
Summary Blueprint Medicines generates growing revenues from its FDA-approved product AYVAKIT/AYVAKYT. AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis. Blueprint reported strong Q1 2024 earnings, achieving $92.5 million in AYVAKIT net product revenues and raising guidance for full-year revenues. Read the full article on Seeking AlphaBlueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Summary Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues up and a strong cash position despite a high burn rate. Market sentiment is robust, supported by strong analyst projections, institutional interest, and stock momentum. I am upgrading my rating to a "strong buy," considering Ayvakit's market potential, financial health, and Blueprint's strategic positioning despite biotech investment risks. Read the full article on Seeking AlphaAnalyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$156m |
| Dec 31 2024 | US$13m | US$821k | -US$67m |
| Sep 30 2024 | n/a | n/a | -US$128m |
| Jun 30 2024 | n/a | n/a | -US$205m |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$782k | -US$507m |
| Sep 30 2023 | n/a | n/a | -US$555m |
| Jun 30 2023 | n/a | n/a | -US$554m |
| Mar 31 2023 | n/a | n/a | -US$581m |
| Dec 31 2022 | US$6m | US$701k | -US$558m |
| Sep 30 2022 | n/a | n/a | -US$718m |
| Jun 30 2022 | n/a | n/a | -US$702m |
| Mar 31 2022 | n/a | n/a | -US$650m |
| Dec 31 2021 | US$4m | US$501k | -US$644m |
| Sep 30 2021 | n/a | n/a | -US$411m |
| Jun 30 2021 | n/a | n/a | US$340m |
| Mar 31 2021 | n/a | n/a | US$325m |
| Dec 31 2020 | US$2m | US$461k | US$314m |
| Sep 30 2020 | n/a | n/a | US$333m |
| Jun 30 2020 | n/a | n/a | -US$395m |
| Mar 31 2020 | n/a | n/a | -US$371m |
| Dec 31 2019 | US$3m | US$432k | -US$348m |
| Sep 30 2019 | n/a | n/a | -US$362m |
| Jun 30 2019 | n/a | n/a | -US$340m |
| Mar 31 2019 | n/a | n/a | -US$267m |
| Dec 31 2018 | US$3m | US$393k | -US$237m |
Vergütung im Vergleich zum Markt: KateDie Gesamtvergütung ($USD13.48M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD8.38M).
Entschädigung vs. Einkommen: KateDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Kate Haviland (49 yo)
Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 3.3yrs | US$13.48m | 0.11% $ 9.1m | |
| Co-Founder & Director | no data | US$549.69k | 0.11% $ 9.6m | |
| Chief Financial Officer | 9.4yrs | US$4.19m | 0.067% $ 5.6m | |
| Chief Operating Officer | 3.3yrs | US$6.54m | 0.032% $ 2.7m | |
| Chief Scientific Officer | 4.2yrs | US$5.13m | 0.082% $ 6.9m | |
| President of Research & Development | 4.8yrs | US$5.50m | 0.049% $ 4.1m | |
| Senior Vice President of Finance and Principal Accounting Officer | no data | keine Daten | 0.026% $ 2.2m | |
| Senior Director & Head of Investor Relations | no data | keine Daten | keine Daten | |
| Executive VP | 8.8yrs | US$2.34m | 0.057% $ 4.8m | |
| Chief People Officer | 5.4yrs | keine Daten | 0.035% $ 3.0m | |
| Senior Vice President of Corporate Affairs | no data | keine Daten | keine Daten | |
| Chief Medical Officer | 5.2yrs | keine Daten | 0.047% $ 3.9m |
Erfahrenes Management: Das Managementteam von BPMC ist erfahren und erfahren (durchschnittliche Amtszeit von 5 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 3.3yrs | US$13.48m | 0.11% $ 9.1m | |
| Co-Founder & Director | 14.3yrs | US$549.69k | 0.11% $ 9.6m | |
| Chair of Scientific Advisory Board | 13.2yrs | US$333.38k | keine Daten | |
| Lead Independent Director | 9.3yrs | US$606.19k | 0.020% $ 1.7m | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board & Independent Director | 14.3yrs | US$569.69k | 0.086% $ 7.2m | |
| Independent Director | 9.4yrs | US$572.59k | 0.0035% $ 289.6k | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 3.6yrs | US$574.69k | 0.017% $ 1.4m | |
| Chairman of the Board of Director | 11yrs | US$586.19k | 0.22% $ 18.7m |
Erfahrener Vorstand: BPMCDie Vorstandsmitglieder sind sehr erfahren ( 10.2 ).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2025/07/17 16:47 |
| Aktienkurs zum Tagesende | 2025/07/17 00:00 |
| Gewinne | 2025/03/31 |
| Jährliche Einnahmen | 2024/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Blueprint Medicines Corporation wird von 10 Analysten beobachtet. 19 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| George Farmer | BMO Capital Markets Equity Research |
| Dane Leone | BTIG |
| Arlinda Lee | Canaccord Genuity |